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ABSTRACT: The human cytidine deaminase APOBEC3G (A3G) is a potent inhibitor of the HIV-1 virus in the absence of viral
infectivity factor (Vif). The molecular mechanism of A3G antiviral activity is primarily attributed to deamination of single-
stranded DNA (ssDNA); however, the nondeamination mechanism also contributes to HIV-1 restriction. The interaction of
A3G with ssDNA and RNA is required for its antiviral activity. Here we used atomic force microscopy to directly visualize A3G−
RNA and A3G−ssDNA complexes and compare them to each other. Our results showed that A3G in A3G−RNA complexes
exists primarily in monomeric−dimeric states, similar to its stoichiometry in complexes with ssDNA. New A3G−RNA complexes
in which A3G binds to two RNA molecules were identiﬁed. These data suggest the existence of two separate RNA binding sites
on A3G. Such complexes were not observed with ssDNA substrates. Time-lapse high-speed atomic force microscopy was applied
to characterize the dynamics of the complexes. The data revealed that the two RNA binding sites have diﬀerent aﬃnities for A3G.
On the basis of the obtained results, a model for the interaction of A3G with RNA is proposed.
APOBEC3G (A3G) belongs to the APOBEC3 family of DNA-
editing cytidine deaminases that are responsible for deami-
nation of HIV-1 cDNA during reverse transcription in the
absence of viral infectivity factor (Vif).1,2 A3G consists of two
zinc-coordinating domains,3 the N-terminal domain (NTD)
that is incapable of catalysis but responsible for binding ssDNA
and RNA4,5 and the C-terminal domain (CTD) that catalyzes
ssDNA deamination.6,7 The primary antiviral activity of A3G is
deamination of the viral ssDNA and the most studied
mechanism of action.7−10 However, there is evidence that
deaminase-independent mechanisms are also involved in the
antiviral activity of A3G.4,11,12 One is the so-called “road block”
mechanism, in which A3G physically blocks the elongation of
reverse transcribed proviral ssDNA,12 and the other includes
RNA-dependent incorporation of newly synthesized A3G into
viral particles.13−16 It was shown that A3G binds to diverse
cellular RNA,14,17−19 but during the encapsidation process,
A3G forms a complex with viral RNA.16 These deaminase-
independent activities include A3G binding capabilities that are
speciﬁc to ssDNA and RNA and involve both A3G domains. It
was shown that the extents of most deaminase-independent
functions of A3G decrease after the introduction of mutations
into the NTD,4 but mutations in the CTD do not completely
abolish the antiviral A3G activity against HIV.20,21
Considerable biochemical and biophysical data are available
for A3G−RNA complexes.2 It was shown that RNA inhibits
A3G catalytic activity by binding to the CTD of A3G. This
suggests a mechanistic explanation for the diﬀerent modes of
binding of A3G22 to ssDNA and RNA. However, no studies
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have directly characterized A3G−RNA complexes or compared
them with A3G−ssDNA complexes. It is currently unclear
whether RNA shares the A3G binding site with ssDNA or if
RNA interacts with a diﬀerent region of A3G. Currently, there
is a lack of direct data about the stoichiometry of A3G−RNA
complexes. It is also not clear whether the A3G stoichiometry
of A3G−RNA complexes diﬀers from the stoichiometry of
A3G−ssDNA complexes.
To address these issues, we characterized properties of
A3G−RNA complexes and compared them with the properties
of A3G−ssDNA complexes. We, for the ﬁrst time, directly
visualized the A3G−RNA complexes with AFM and estimated
the stoichiometry of A3G in these complexes. From experi-
ments performed for both A3G−ssDNA and A3G−RNA
complexes, we conclude that A3G appears in similar oligomeric
states on both substrates. However, a remarkable diﬀerence in
assemblies of ssDNA and RNA complexed with A3G was
observed. Similar to the case for A3G−ssDNA complexes,
when one RNA molecule bound to A3G, we also observed two
RNA molecules bound to A3G. Complexes containing two
molecules of ssDNA bound to A3G were never observed. By
analyzing the data for each A3G domain independently, we
show that RNA forms complexes with both the sNTD and
CTD-191−384-E259A, while ssDNA is not able to form such
complexes. Together, these results indicate the existence of an
additional region on A3G diﬀerent from ssDNA that is capable
of binding RNA. The dynamic behavior of the A3G−RNA
complexes suggests that the two binding regions of A3G have
diﬀerent aﬃnities for RNA. On the basis of these results, a
model for binding of RNA to A3G is discussed.
■ MATERIALS AND METHODS
RNA Hybrid Substrate Preparation. The hybrid RNA
substrate was assembled like the hybrid DNA substrate as
described in ref 23. The schematic of the procedure is shown in
Figure S1. First, the DNA−RNA hybrid consisting of a 21-
nucleotide ssDNA and a 69-nucleotide RNA strand was
synthesized (Integrated DNA Technology, Coralville, IA).
Second, phosphorylated 18-mer ssDNA was annealed in a 1:1
ratio with a 90-nucleotide hybrid ssDNA−RNA strand to create
an 18 bp dsDNA region with three sticky ends and a 69-
nucleotide RNA tail. Third, the strand formed after annealing
18 bp dsDNA with a 69-nucleotide RNA tail was ligated with a
previously gel-puriﬁed 124 bp dsDNA fragment with three-
nucleotide sticky ends. As a result, the hybrid RNA product
consists of 145 bp dsDNA and a 69-nucleotide RNA tail. The
ligated product was immediately treated with phenol,
precipitated with ethanol, and stored at −80 °C. To protect
the ssRNA from degradation, RNAsecure inactivation reagent
(Thermo Fisher Scientiﬁc) was added at each step of the hybrid
RNA assembly process. Speciﬁcally, all DEPC-treated buﬀers
with 1× RNAsecure inactivation reagent were heated to 60 °C
for 10 min and then cooled to room temperature.
The gel electrophoresis of the ligated RNA hybrid product is
shown in Figure S2A, and the estimated yield of the ligated
product was 78%. The ﬁnal product of the RNA hybrid has 145
bp dsDNA fused with 69-nucleotide RNA, as chematically
shown in Figure S3B.
DNA Hybrid Substrate Preparation. The hybrid DNA
substrate was assembled as described in detail23 and is similar to
the assembly of the RNA hybrid, described above. Brieﬂy, the
89-nucleotide sequence was annealed at a 1:1 ratio with
phosphorylated 20-mer followed by ligation overnight at 16 °C
with a previously gel-puriﬁed 356 bp dsDNA fragment with
three-nucleotide sticky ends. The ligated product containing a
69-nucleotide ssDNA region attached to the 376 bp dsDNA
was immediately treated with phenol, precipitated with ethanol,
and stored at −20 °C. The gel electrophoresis for the ligated
ssDNA hybrid product is shown in Figure S2B. The yield of the
ligated product was 90%. The ﬁnal product of the ssDNA
hybrid has 376 bp dsDNA fused with 69-nucleotide ssDNA, as
shown in Figure S3A.
Preparation of Complexes of A3G with RNA and DNA.
Full length human A3G was puriﬁed as described in refs 23−25.
The A3G−ssDNA and A3G−RNA complexes were formed at a
4:1 protein:DNA ratio in reaction buﬀer containing 50 mM
HEPES (pH 7.5), 100 mM NaCl, 5 mM MgCl2, and 1 mM
DTT and incubated for 15 min at 37 °C. All components of the
buﬀer were prepared in DEPC-treated deionized water
(AquaMax) and treated with RNAsecure inactivation reagent,
as described above. To ensure that treatment does not aﬀect
the activity of A3G, the A3G−ssDNA complex was prepared at
a 4:1 ratio. The yield of the A3G−ssDNA complex (∼83%) was
similar to the yield of the A3G−ssDNA complexes obtained
without treatment,26 which shows that RNAsecure inactivation
reagent-treated A3G maintains its binding activity. The
schematic for formation of the A3G complex between the
ssDNA hybrid and the RNA hybrid is shown in Figure S3. The
protein, depicted as green spheres, forms complexes that are
seen at the end of the 376 bp dsDNA for the A3G−ssDNA
complex (C) and the 145 bp RNA (D).
Puriﬁcation of sNTD and CTD-191−384-E259A. For the
domain experiments, we used two soluble variants of the NTD
and CTD of human A3G, sNTD27 and inactive CTD-
191−384-E259A,28,29 respectively. Despite sequence variability
(see the sequences of the sNTD and CTD-191−384-E259A in
Figure S4), previous studies suggested that the sNTD and
CTD-191−384-E259A are structurally similar to the wild-type
NTD and CTD.29 The pGEX6P-1 expression vector carrying
either the sNTD or the CTD-191−384-E259A (inactive
variant) genes fused with an N-terminal GST tag was
transformed into BL21 (DE3) cells (Invitrogen).27,28 The
amino acid sequences for the sNTD and CTD-191−384-
E259A are shown in Figure S4. Cells were grown in LB
medium at 37 °C until they reached an optical density of 0.5−
0.6 at 600 nm. Then the temperature was changed to 17 °C,
and cells were induced by adding 0.2 mM isopropyl β-D-1-
thiogalactopyranoside at an optical density of 0.6−0.8. Cells
were further grown overnight at 17 °C.
All steps for protein puriﬁcation were performed at 4 °C,
unless speciﬁed. Escherichia coli cells were harvested by
centrifugation and resuspended in lysis buﬀer [50 mM sodium
phosphate (pH 7.3), 150 mM NaCl, 25 mM ZnCl2, 2 mM
DTT, and 0.002% Tween 20] and protease inhibitor (Roche,
Basel, Switzerland). The suspended cells were disrupted by
sonication, and then cells debris was separated by centrifugation
at 20000 rpm for 30 min. The supernatant containing the
desired protein was applied to Glutathione-Sepharose (GE
Healthcare Life Science) beads, pre-equilibrated with lysis
buﬀer, and agitated for ∼2 h. The beads were washed with Pre-
Scission Protease cleavage buﬀer [50 mM sodium phosphate
(pH 7.5), 100 mM NaCl, 10 mM ZnCl2, 2 mM DTT, and
0.002% Tween 20] and incubated with Pre-Scission protease
(GE Healthcare Life Science) overnight. GST free proteins
were separated from beads by centrifugation. The purity and
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concentration of the proteins were measured by gel electro-
phoresis and UV spectroscopy.
Preparation of Complexes of RNA with the sNTD and
CTD-191−384-E259A. Complexes of each domain and RNA
were prepared in the treated binding buﬀer [50 mM HEPES
(pH 7.5), 100 mM NaCl, 5 mM MgCl2, and 1 mM DTT] and
incubated at 37 °C for 15 min, as described above. The
protein:RNA or protein:ssDNA ratio was 48:1 for both the
CTD-191−384-E259A and the sNTD.
Sample Preparation and AFM Imaging in Air. The
AFM experiments were performed with the use of an APS-
functionalized mica surface as described in detail previously.30
Speciﬁcally, 5 μL of the complexes was deposited onto a mica
surface for 2 min, washed with DEPC-treated, deionized
(AquaMax) water, and dried with argon gas. AFM images were
acquired in tapping mode in air with a Multimode IIIa system
(Bruker, Santa Barbara, CA). Silicon TESP probes from Bruker
with a spring constant of around 42 pN/nm and resonance
frequencies around 320 kHz were used.
Sample Preparation and HS-AFM Imaging in Liquid.
The methodology for the sample preparation for high-speed
AFM (HS-AFM) imaging is described in ref 30. Brieﬂy, a 1.5
mm diameter APS-treated mica disk was mounted on the top of
the cylinder stage that was partially submerged in binding buﬀer
[50 mM HEPES (pH 7.5), 100 mM NaCl, 5 mM MgCl2, and 1
mM DTT]. Two microliters of the complexes was deposit onto
the APS mica disc for 2 min to allow the complexes to attach to
the mica surface. The surface was then washed with binding
buﬀer, and the cylinder stage with the attached sample was
immediately immersed in binding buﬀer to prevent the sample
from drying. The data were acquired by continuous scanning of
the selected area (200 nm × 200 nm) with a scan rate of 398
ms/frame. The tips for imaging were grown under an electron
beam using short cantilevers (BL-AC10DS-A2, Olympus) with
a spring constant between 0.1 and 0.2 N/m and a resonance
frequency of 400−1000 kHz.
Data Analysis. For each type of complex, the protein
volume was obtained using the cross-section feature of the
FemtoScan Online software (Advance Technologies Center,
Moscow, Russia) as described in detail in refs 23 and 31. The
data for protein volume were assembled as a histogram using
Origin 6.0 (OriginLab, Northampton, MA).
■ RESULTS
Characterization of Complexes of A3G with RNA. AFM
studies of A3G−RNA complexes were performed using the
hybrid substrate approach described in refs 23, 25, and 32. In
this approach, RNA or ssDNA is spliced with the DNA duplex
that functions as a tag. The substrate is shown schematically in
Figure 1A, in which the DNA duplex is depicted with a black
line and the RNA tail is shown as a gray line (see Figure S3B,D
for speciﬁcs of substrate assembly). During formation of the
complex, A3G binds RNA and appeares at the end of the
dsDNA tag. In our setup, the RNA hybrid substrate consists of
a 145 bp dsDNA tag and a 69-nucleotide RNA tail (see
Materials and Methods and Figure S3 for details).
A3G−RNA complexes were assembled at a 4:1 protein:RNA
ratio, and examples of typical AFM images for the complexes
are shown in Figure 1B. A3G−RNA complexes appear as bright
globular features (blobs) at the end of the dsDNA tag and are
marked with the number 1. This approach allows us to directly
visualize the A3G−RNA complexes and conﬁrm that A3G
eﬃciently binds RNA. Note that the brightness and size of the
blobs vary, suggesting that diﬀerent oligomeric states of A3G
exist when it is complexed with RNA. To compare the
oligomerization states of A3G in complex with RNA and
ssDNA, we characterized the protein stoichiometry of A3G−
RNA and A3G−ssDNA complexes.
In these experiments, we used a hybrid DNA substrate with
the same length of ssDNA as RNA (69 nucleotides) and a
much longer DNA duplex tag (376 bp). Because of the large
diﬀerence in the length of the dsDNA tags, we were able to
distinguish and characterize complexes of A3G with RNA and
ssDNA in the mixture of both substrates. Such an experimental
setup eliminates the potential concern about the variability of
the experimental conditions when the complexes are prepared
and visualized with each substrate separately. As in the previous
experiment, RNA and ssDNA substrates were mixed with A3G
at 4:1 protein:substrate ratio. Figure 2 shows a typical AFM
image for the mixed complexes. As seen in the images, A3G
complexes appear as bright blobs at the ends of both short
(RNA) and long (ssDNA) substrates. In this image, the
complexes formed with the RNA hybrid are marked with the
number 1 and complexes formed with the ssDNA hybrid with
the number 2. We estimated the stoichiometry of both types of
complexes by measuring the protein volumes from AFM
images. The histograms for the protein volumes were obtained
from more than 150 molecules for both A3G−RNA and A3G−
ssDNA complexes and are shown in panels A and B of Figure 2,
respectively. The protein volumes in the images were measured
and translated into protein molecular weights, as described in
refs 23 and 30. The two distributions are similar to each other
and show a majority of A3G for both substrates as monomers
and dimers with a mixture of larger oligomers.
Characterization of Complexes of A3G with Two RNA
Molecules. During the analysis of AFM images of A3G with
the RNA substrate, we found complexes composed of two RNA
molecules attached to A3G. Figure 3 shows the example of this
type of complex labeled with the number 2, along with a regular
A3G−RNA complex labeld with the number 1. The yield of
complexes, labeled with the number 2, is ∼10% of all the A3G−
RNA complexes. The gallery of selected images in which A3G
binds two RNA substrates is shown in Figure 3A−D. The sizes
of A3G in these complexes varied. Two RNA molecules can be
bound to the A3G monomer (Figure 3A,B) or dimer (Figure
Figure 1. AFM images of A3G−RNA complexes. (A) Hybrid RNA
substrate consisting of the dsDNA tag (black line) and the RNA tail
(gray line) forming the complex with A3G (imaged by AFM). (B)
Image of the hybrid RNA substrate complexed with A3G protein.
Complexes appear as bright blobs clearly seen at the end of the
dsDNA tag. The complexes are marked with the number 1.
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3C,D). Note that complexes with two ssDNA molecules
attached to A3G were not found, suggesting that the formation
of complexes with two RNA molecules is a unique feature of
binding of RNA to A3G.
Next, we imaged complexes formed by A3G with the mixture
of ssDNA and RNA substrates, and the typical AFM image is
presented in Figure 4 at the left. The AFM image shows that in
addition to complexes of A3G with RNA (marked with the
number 1) and ssDNA (marked with the number 2), there are
Figure 2. Determination of the stoichiometry of A3G−RNA and A3G−ssDNA complexes. AFM image of A3G complexes with RNA (1) and
ssDNA (2) substrates. The distributions of the protein volume for more than 150 complexes of (A) A3G with RNA and (B) A3G with ssDNA were
calculated on the basis of the diﬀerences in the length of the dsDNA parts for RNA and ssDNA substrates (see Figure S3 for schematics). The blue
and brown arrows indicate the volume values for the A3G monomer and dimer, respectively.
Figure 3. AFM images of A3G−RNA complexes. The number 1 marks the regular A3G−RNA complexes, and the number 2 marks complexes with
two RNA molecules bound to A3G. At the right is the gallery of AFM images that show the two RNA molecules attached to the (A and B) A3G
monomer and (C and D) A3G dimer. The image size is 200 nm.
Figure 4. AFM image of complexes of A3G with the RNA/ssDNA mixture. The number 1 marks A3G−RNA complexes; the number 2 marks A3G−
ssDNA complexes, and the number 3 marks A3G−RNA−ssDNA complexes. The gallery of AFM images (at the right) shows chimeric ssDNA and
RNA complexes bound to the (A and B) A3G monomer and (C and D) dimer. The image size is 200 nm.
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complexes that contain both ssDNA and RNA substrates
bound to the same A3G protein (marked with the number 3).
However, the yield of these chimeric complexes is quite low,
∼2% of all the complexes. The gallery of chimeric complexes is
shown in Figure 4A−D. The sizes of A3G vary, suggesting that
in chimera A3G complexes exist as a monomer (Figure 4A,B),
as well as a dimer (Figure 4C,D).
Characterization of Complexes of RNA with the sNTD
and CTD-191−384-E259A. To determine which domain
contributes to A3G−RNA interactions, we assembled com-
plexes of RNA with the isolated CTD-191−384-E259A or the
sNTD. Typical AFM images of CTD-191−384-E259A−RNA
and sNTD−RNA complexes are presented in panels A and B of
Figure 5, respectively. As in the images obtained for the full size
A3G (Figures 1−4), complexes with individual domains are
identiﬁed as blobs located at the end of the dsDNA tag, as
indicated with arrows in Figure 5. However, the sizes of the
blobs for both domains are smaller that the sizes obtained with
the full size protein, which reﬂect the smaller sizes of the
individual domains compared to full length A3G. Note that
RNA binds less eﬃciently to the individual the CTD-2K3A-
E259A and sNTD than to full size A3G; therefore, it was
necessary to use protein:substrate molar ratio as large as 48:1 to
obtain a reasonable yield of complexes.
Yields of complexes for both domains were 22 and 42% for
sNTD−RNA and CTD-191−384-E259A−RNA complexes,
respectively. Our observation of 2-fold lower yield of the
sNTD−RNA complex does not correlate with previous studies
that suggest that the NTD plays a major role in RNA binding.33
The 2-fold lower yield of the sNTD−RNA complex is most
likely due to the mutation introduced into the sNTD variant to
make it soluble.27 However, the fact that the CTD-2K3A-
E259A forms complexes with RNA suggests that the CTD also
contribute to RNA binding with the full-size A3G.
Under our experimental conditions, we do not observe any
formation of a complex of ssDNA with either the CTD-
191−384-E259A or the sNTD (see Figure S5). The fact that no
complex formed between the CTD-191−384-E259A and
ssDNA is consistent with previous observations by Xiao et
al.,34 who showed that the hA3G−CTD complex produces no
shift or a very weak band shift in a gel shift assay with ssDNA,
even at signiﬁcantly higher hA3G−CTD complex concen-
trations.34 However, the lack of complex formation between the
sNTD and ssDNA could be a reﬂection of mutations
introduced into the sNTD. Therefore, our observations suggest
that both the CTD and the NTD are required to achieve high-
aﬃnity binding to ssDNA.
Dynamics of A3G−RNA Complexes. To follow the
dynamics of A3G−RNA complexes, we used time-lapse HS-
AFM. In this AFM mode, imaging is performed in solution,
which eliminates the potential concern of sample drying.
Additionally, time-lapse imaging over the same area allows one
to follow the dynamics of the complex. The acquisition of data
during HS-AFM experiments is 1000 times faster than in
regular time-lapse AFM, which allows us to follow the dynamics
of the complex on the millisecond time scale.
Figure 6 shows three frames of 52 from Movie 1 that
demonstrate the dissociation process of the A3G−RNA
complex. The initial A3G−RNA complex in frame 6 appears
as a globular feature. Over time, one monomer dissociates
Figure 5. Complexes of RNA with the (A) CTD-2K3A-E259A and (B) sNTD. A few typical complexes are indicated with arrows. The yield of
RNA−CTD-2K3A-E259A complexes is 42%, and the yield of RNA−sNTD complexes is 22%.
Figure 6. HS-AFM images of RNA−A3G complexes. Selected frames of 52 assembled as Movie 1. The circles indicate the complex undergoing
dissociation. The scanning rate corresponds to 398 ms/frame.
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(frame 17) while the other remains attached to RNA,
suggesting that A3G was initially a dimer. The remaining
monomeric complex was stable and dissociated only at frame
49. This two-step dissociation pattern was observed in seven
diﬀerent movies, suggesting that this is a common dissociation
pathway for dimeric A3G−RNA complexes. A similar pattern
was observed in our experiments with A3G−ssDNA com-
plexes.30 The two-step dissociation pattern suggests that free
protein, dissociated from the complex, is mostly monomeric.
Indeed, the measured volumes of free protein from dry AFM
images of complexes of A3G with RNA and ssDNA substrates
show that A3G exists primarily in the monomeric state (Figure
S6), thereby supporting our hypothesis.
Next, we used time-lapse HS-AFM to characterize the
dynamics of complexes in which A3G binds two RNA
molecules. The three frames in Figure 7 illustrate the dynamics
of the complex formed by the A3G monomer. The entire
dynamics can be seen in Movie 2. Initially, the A3G monomer
forms a complex with two RNA molecules (frame 1). Then,
one of the RNA molecules dissociates (frame 25), while
another RNA molecule remains bound to the A3G monomer.
This RNA eventually dissociates, so the fully dissociated
complex is shown in frame 33. This dissociation pattern was
observed in ﬁve diﬀerent movies, but simultaneous dissociation
of two RNA molecules was never observed. This suggests that
the eﬃciency of binding of RNA to two A3G sites within these
complexes is diﬀerent.
Four frames in Figure 8 show the dissociation process for the
complexes of two RNA molecules bound to the A3G dimer
(frame 3), and the entire process can be seen in Movie 3. In
frame 57, one RNA molecule dissociates, leaving the A3G
dimer attached to the second RNA molecule. This pattern is
similar to that in Figure 6 in which one RNA molecule binds to
the A3G dimer. In frame 162, the A3G monomer dissociates
from the complex, demonstrating a two-step dissociation
pattern. Finally, in frame 215, the A3G monomer dissociates
from RNA, suggesting stronger interaction of RNA with one
A3G region compared to the strength of the monomer−
monomer bond in the A3G dimer.
■ DISCUSSION
Here we present the ﬁrst direct visualization and dynamic
behavior of A3G−RNA complexes and reveal a number of
novel properties that might have important biological
implications.
Speciﬁcity and Stoichiometry of A3G−RNA Com-
plexes. Our results show that A3G binds RNA with the
same binding eﬃciency as ssDNA, despite the lack of
deaminase activity for RNA. Moreover, the stoichiometries of
A3G in complex with RNA and ssDNA as determined from the
volume measurements are very similar to one another.
Importantly, these measurements were taken from the samples
in which two diﬀerent substrates were mixed together, so
potential concerns about the variability of the reaction
conditions have been eliminated. The primary species in
these complexes were monomers and dimers, with a very low
percentage of higher-order oligomers. Although there was a
discussion in the literature regarding the stimulation of A3G
oligomerization upon binding to RNA,14,35,36 our results
primarily show the existence of monomeric and dimeric A3G
states bound to RNA. These results are in line with the data
presented in ref 37 that showed the capability of A3G
monomers to bind to RNA
Time-lapse HS-AFM data allowed us to follow the dynamics
of the A3G−RNA complexes (Figure 6). The data demonstrate
that the dissociation of the complex containing the A3G dimer
is a two-step process in which one monomer dissociates prior
to the dissociation of the A3G−RNA complex. These ﬁndings
suggest that in these complexes, A3G−RNA interactions are
stronger than interprotein interactions. This is a property
similar to one we observed for complexes of A3G dimers with
ssDNA.30
Figure 7. HS-AFM images of the dissociation of the A3G monomer complexed with RNA. Selected frames of 36 assembled as Movie 2. The
complexes undergoing dissociation are circled. The scanning rate corresponds to 398 ms/frame.
Figure 8. HS-AFM images of the dissociation of the A3G dimer complexed with RNA. Selected frames of 226 assembled as Movie 3. The circles
indicate the complex undergoing dissociation. The scanning rate corresponds to 398 ms/frame.
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Two RNA Molecules Binding to A3G. One of our novel
ﬁndings is the formation of complexes in which two RNA
molecules are bound to A3G. This property of RNA is entirely
diﬀerent from that of ssDNA, which never binds to A3G in
pairs. Moreover, the appearance of the chimera complexes that
contain one ssDNA and one RNA bound to A3G strongly
indicate an extra binding region on A3G for RNA only.
Therefore, our data demonstrate that while ssDNA has only
one binding site on A3G, RNA has an additional binding region
on A3G. This ﬁnding is consistent with the data presented in
ref 22 that revealed an additional binding region for RNA
located at the N-terminal domain at amino acids 15−29, 41−
52, and 83−99.
Using HS-AFM (Figure 7), we also were able to characterize
the dynamics of such complexes. The time-lapse studies show
that dissociation of RNA molecules from two RNA−A3G
complexes is a two-step process, suggesting that the eﬃciency
of binding of RNA to two A3G sites is diﬀerent. The
dissociation of the complex when the A3G monomer bound to
two RNA molecules suggests that one RNA binding region of
A3G interacts stronger with RNA than a second does. This
eﬀect is even more pronounced when two RNA molecules are
bound to the A3G dimer (see Movie 3 and selected frames in
Figure 8). In this case, one RNA molecule dissociates ﬁrst,
leaving the A3G dimer still attached to the other RNA
molecule. These data conﬁrm that the two A3G sites have
diﬀerent binding eﬃciencies with RNA and indicate that the
interaction between RNA and one of the A3G binding sites is
weaker than protein−protein interaction in the A3G dimer.
Complexes of RNA and ssDNA with the NTD and CTD.
The existence of two regions on A3G that are capable of
binding to RNA is fully supported by the results from
experiments with RNA in complex with the sNTD and CTD-
191−384-E259A. Indeed, our results clearly show that RNA is
capable of binding the CTD-191−384-E259A or sNTD, but no
such complexes were observed with ssDNA. Our observation of
chimeric complexes in which one ssDNA molecule and one
RNA molecule are bound to A3G also conﬁrms that RNA has
an additional binding site on A3G that is separate from the one
that binds to ssDNA.
Model for A3G−RNA Complexes. Our results clearly
demonstrate that A3G has two separate regions for binding
RNA, but only one for ssDNA. The presence of an additional
RNA binding site is directly supported by the appearance of
two RNA molecules bound to A3G and chimeric complexes
consisting of one ssDNA and one RNA molecule bound to
A3G simultaneously. From the dynamic behavior of two A3G−
RNA complexes, we showed that these two sites have a
diﬀerent binding aﬃnity for A3G. Together, these data allow us
to propose a model for binding of RNA to A3G, which is
illustrated in Figure 9. The RNA hybrid on the cartoon consists
of two parts, a short thick blue bar representing the dsDNA tag
and a thin blue line representing the RNA tail; the ssDNA
hybrid has a long red thick bar representing the dsDNA tag
with a thin red line representing the ssDNA tail. The model in
which two RNA molecules are bound to two A3G sites is
indicated with the number 1. We suggest that the site, shown as
a long blue line on the right, is the strongest RNA binding site
on A3G and includes both the CTD and the NTD, similar to
A3G−ssDNA complexes as described in refs 30 and 37 and
shown by the red thin line in the cartoon (marked with the
number 2 on the right). Indeed, the majority of the A3G−RNA
complexes contain one RNA bound to A3G. This model is also
supported by our data showing that no ssDNA complexes are
formed with either the CTD-191−384-E259A or the sNTD,
even at a very high protein:substrate ratio.
We suggest that the second, additional RNA binding site on
A3G is located on the NTD, as illustrated by the thin blue line
on the left and marked with the number 1. The model for this
site on A3G is derived from the fact that RNA may form
complexes with the sNTD. The data obtained from the
dynamic behavior of two RNA molecules bound to a monomer
or dimer of A3G conﬁrm that one of the RNA binding sites on
A3G is less eﬃcient than the other. The existence of chimeric
complexes in which one RNA and one ssDNA are bound to
A3G also provides additional support for this model.
Model 2, depicted in the cartoon in Figure 9, illustrates the
chimeric complex with ssDNA and RNA attached to A3G. The
ssDNA is shown as a thin red line covering the CTD and the
NTD on A3G (see the number 2). The RNA molecule is
shown as a blue line that is in contact with only the NTD (see
the number 2), which is the additional binding site for RNA
within A3G. We suggest that the existence of A3G complexes
containing two RNA molecules or one RNA and one ssDNA
attached to A3G is more rare than the existence of regular
RNA−A3G complexes because RNA binds less eﬃciently to
the NTD than to both the CTD and the NTD.
Model 3 shows complexes consisting of two RNA molecules
interacting with the A3G dimer. The dynamic behavior of
complexes illustrated in Figure 8 (Movie 3) shows that one
RNA molecule dissociates ﬁrst, suggesting that this RNA was
bound to the weaker binding site. Moreover, it shows that
protein−protein interactions within the A3G dimer are
stronger than the interactions between RNA and A3G at this
binding site.
Note that the data obtained from complexes consisting of
two RNA molecules or one RNA and one ssDNA molecule
bound to the A3G monomer allow us to speculate about the
Figure 9.Model of the A3G−RNA complex. Proposed model of A3G in complex with two RNA molecules and with RNA and ssDNA. The blue and
red thin lines represent RNA and ssDNA, respectively. The bars represent the dsDNA tags for RNA (short blue bar) and dsDNA (long red bar) (see
the schematic for the substrate design in Figure S3): (1) complex with two RNA molecules attached to the A3G monomer, (2) complex with one
ssDNA and one RNA attached to the A3G monomer, and (3) complex with two RNA molecules attached to the hypothesized assembly of the A3G
dimer.
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assembly of A3G into dimers. On the basis of the proposed
model for A3G monomer complexes, the most probable
arrangement for dimeric A3G is a head-to-tail structure. Indeed,
when the A3G dimer has a head-to-tail structure, two RNA
molecules or one ssDNA and one RNA molecule have a
binding pattern similar to the pattern associated with A3G
monomeric complexes. Recently, the head-to-tail dimer
conformation was suggested as the most probable structural
model of full length A3G.38
In summary, single-molecule AFM imaging and HS-AFM
approaches allowed us to directly visualize RNA−A3G
complexes and follow their dynamic behavior. The hybrid
design in which dsDNA is used as a ruler to unambiguously
identify each individual ssDNA and RNA complex with A3G
allowed us to directly compare the A3G stoichiometry in the
complexes without the ambiguity of separate sample prepara-
tions. The analysis of the data shows similar oligomerization
states of A3G bound to RNA and ssDNA. Moreover, new,
previously unknown, A3G−RNA complexes have been
discovered. Two separate RNA binding regions on A3G have
been observed and characterized. Finally, we proposed a model
for diﬀerent mechanisms for binding of RNA and ssDNA to
A3G.
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